Topical JAK Inhibitor Shows Improvement for PN

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a phase 3 trial shows.
Medscape Medical News

source https://www.medscape.com/viewarticle/topical-ruxolitinib-improves-itch-blistering-prurigo-2025a10006b2?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?